Policy

Explore 5 FAQs on CDC opioid guidelines, including dosing, tapering, monitoring, and managed care strategies to reduce overdose risk.

The authors examined experiences with Pennsylvania’s implementation of opioid settlement funds, identifying 7 themes and highlighting opportunities to improve administration and ensure effective fund distribution.

The 2018 permanent authorization of dual-eligible special needs plans marked a significant long-term commitment by policy makers and coincided with substantial growth in plan offerings and enrollment.

Black Maternal Health Week spotlights disparities, Medicaid postpartum coverage gains, and ongoing policy efforts to reduce maternal mortality.

Experts from AMCP emphasize the importance of drug-adjacent early detection tests and screening ability to improve patient outcomes.

A new industry report underscores the momentum—and the work ahead—as gene-, cell-, and tissue-based treatments move from academic health systems into community care.

Patty Taddei-Allen, PharmD, MBA, examines how co-pay accumulators, maximizers, and AFPs shift costs, impact rebates, and create access challenges for patients.

The FDA is encouraging drug sponsors to pursue a new indication for testosterone replacement therapy.

High co-payments for potentially curative cell and gene therapies create avoidable access barriers; value-based insurance design should eliminate patient cost sharing for these therapies.

A July 2026 advisory meeting will evaluate whether broader compounding access to peptides is justified despite concerns around safety, efficacy, and limited clinical evidence.

Adam Colburn, JD, highlights 3 federal bills to expand value-based care, digital therapeutics, and pharmacist reimbursement across Medicare and Medicaid.

Steven Kheloussi, PharmD, explains how care coordination and transparent policies can improve MS treatment adherence, streamline access, and balance costs.

KFF Health Tracking Poll finds prior authorization tops patient hassles; Drew Altman, PhD, warns complexity delays care, hitting chronic patients hardest.

Experts at AMCP 2026 outlined volatility across the health care landscape that may impact the upcoming midterm elections.

John Barkett, MBA, discusses recent regulatory proposals to make massive health plan price files more usable.

Esketamine's monotherapy approval and new real-world data are forcing a reckoning for managed care.

Oral semaglutide hasn't shifted prescribing as expected. Shawn Davis, MD, discusses what access and policy changes are needed to close the coverage gap.

A phase 1 clinical trial specialist, Nancy L. Lewis, MD, MBS, FACP, most recently spent more than a decade at Novartis and was previously a faculty member at Fox Chase Cancer Center and Thomas Jefferson University Hospital.

ACIP changes threaten vaccine coverage and raise costs, according to a roundtable of experts warning of widening disparities and long-term public health risks.

The cap cut quarterly spending by the hundreds and lowered A1c levels but failed to expand the pool of insulin users.

Steven Kheloussi, PharmD, explores how smarter clinical tools, multidisciplinary teams, and better care coordination can improve outcomes for people with MS.

Findings from a randomized controlled trial on reducing information barriers for consumers selecting primary care clinics in a tiered network design demonstrate limited marginal effect of the intervention.

Inpatient encounters for Medicare patients 65 years and older are associated with higher coding intensity compared with commercially insured, Medicaid, or self-pay hospitalizations for those same individuals prior to age 65 years.

The law stems from the case of a beneficiary of the state workers health plan, repeatedly denied an alternative cancer treatment, only to be approved after he was too ill to be a candidate.

Federal pharmacy benefit manager transparency reforms must contend with concentrated pharmaceutical markets that lack competitive conditions. Learnings from transparency will shape future drug pricing reforms.